Preoperative iodine-123 meta-iodobenzylguanidine imaging is a novel predictor of left ventricular reverse remodeling during treatment with a left ventricular assist device

Journal of Artificial Organs

Volumn 19, Issue 1, 2016, Pages 29-36

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Nitta, Daisuke ^a   Kinoshita, Osamu ^a   Nawata, Kan ^a   Ono, Minoru ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Nuclear medicine; Washout rate

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; (3 IODOBENZYL)GUANIDINE;

ADULT; AORTA VALVE; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; EXERCISE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICULAR REVERSE REMODELING; HEART SCINTISCANNING; HEART VENTRICLE REMODELING; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RADIOLOGICAL PARAMETERS; REGION OF INTEREST; ADVERSE EFFECTS; CARDIOMYOPATHY, DILATED; DIAGNOSTIC IMAGING; HEART ASSIST DEVICE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; YOUNG ADULT;

3-IODOBENZYLGUANIDINE; ADULT; AORTIC VALVE; CARDIOMYOPATHY, DILATED; FEMALE; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 84961053023     PISSN: 14347229     EISSN: 16190904     Source Type: Journal    
DOI: 10.1007/s10047-015-0857-6     Document Type: Article

References (29)

1. Kinugawa K. How to treat stage D heart failure? When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J. 2011;75(9):2038–45.
2. Kirklin JK, Naftel DC, Pagani FD, et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transpl. 2014;33(6):555–64.
3. Imamura T, Kinugawa K, Fujino T, et al. Aortic insufficiency in patients with sustained left ventricular systolic dysfunction after axial flow assist device implantation. Circ J. 2015;79(1):104–11. doi:10.1253/circj.CJ-14-0944.
4. Drakos SG, Wever-Pinzon O, Selzman CH, et al. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol. 2013;61(19):1985–94.
5. Imamura T, Kinugawa K, Hatano M, et al. Preoperative beta-blocker treatment is a key for deciding left ventricular assist device implantation strategy as a bridge to recovery. J Artif Organs. 2014;17(1):23–32.
6. Wieland DM, Rosenspire KC, Hutchins GD, et al. Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J Med Chem. 1990;33(3):956–64.
7. Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22(1):1–12.
8. Kuwabara Y, Tamaki N, Nakata T, Yamashina S, Yamazaki J. Determination of the survival rate in patients with congestive heart failure stratified by (1)(2)(3)I-MIBG imaging: a meta-analysis from the studies performed in Japan. Ann Nucl Med. 2011;25(2):101–7.
9. Currie GM, Iqbal B, Wheat JM, et al. Risk stratification in heart failure using (1)(2)(3)I-MIBG. J Nucl Med Technol. 2011;39(4):295–301.
10. Miranda SM, Moscavitch SD, Carestiato LR, et al. Cardiac I123-MIBG correlates better than ejection fraction with symptoms severity in systolic heart failure. Arq Bras Cardiol. 2013;101(1):4–8.
11. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212–21.
12. Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53(5):426–35.
13. Martins da Silva MI, Vidigal Ferreira MJ, Morao Moreira AP, Martins da Silva MI. Iodine-123-metaiodobenzylguanidine scintigraphy in risk stratification of sudden death in heart failure. Rev Port Cardiol. 2013;32(6):509–16.
14. Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging. 2013;6(7):772–84.
15. Shah AM, Bourgoun M, Narula J, Jacobson AF, Solomon SD. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure. JACC Cardiovasc Imaging. 2012;5(11):1139–46.
16. Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41(2):231–8.
17. Momose M, Okayama D, Nagamatsu H, Kondo C, Hagiwara N, Sakai S. Long-term prognostic stratification by a combination of (123)I-metaiodobenzylguanidine scintigraphy and ejection fraction in dilated cardiomyopathy. Ann Nucl Med. 2011;25(6):419–24.
18. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33(3):759–66.
19. Cha YM, Chareonthaitawee P, Dong YX, et al. Cardiac sympathetic reserve and response to cardiac resynchronization therapy. Circ Heart Fail. 2011;4(3):339–44.
20. Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy—clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J. 2001;141(4):645–52.
21. Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. JACC Cardiovasc Imaging. 2010;3(1):64–70.
22. George RS, Birks EJ, Cheetham A, et al. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013;15(9):1035–43.
23. Imamura T, Kinugawa K, Nitta D, Hatano M, Ono M. Opening of aortic valve during exercise is key to preventing development of aortic insufficiency during ventricular assist device treatment. ASAIO J. 2015. doi:10.1097/MAT.0000000000000247.
24. Kato TS, Chokshi A, Singh P, et al. Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail. 2011;4(5):546–53.
25. Simon MA, Kormos RL, Murali S, et al. Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation. 2005;112(9 Suppl):I32–6.
26. Saito S, Yamazaki K, Nishinaka T, et al. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS. J Heart Lung Transpl. 2014;33(6):599–608.
27. Saito S, Matsumiya G, Sakaguchi T, et al. Cardiac fibrosis and cellular hypertrophy decrease the degree of reverse remodeling and improvement in cardiac function during left ventricular assist. J Heart Lung Transpl. 2010;29(6):672–9.
28. Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging. 2009;36(4):555–9.
29. Imamura T, Kinugawa K, Nitta D, et al. Lower rotation speed stimulates sympathetic activation during continuous-flow left ventricular assist device treatment. J Artif Organs. 2015;18(1):20–6.